Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
This is a Phase II study to evaluate the efficacy and safety of savolitinib monotherapy (600 mg once daily) in papillary renal cell carcinoma (“PRCC”) in the United States, Canada and Europe. PRCC represents about 14% of all new cases of kidney cancer.10/15/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 15, 2015 Category: Urology & Nephrology Source Type: news

Silencing Estrogen Receptor-β with siRNA in Cultured Cells
Estrogen receptors α and β (ERα and ERβ) are the two genomic estrogen receptors. ERβ was the second of these receptors to be discovered; its structure is similar to that of ERα but they are different in histological distribution. However, the functions of ERα versus ERβ are still unclear. The ability of small interfering RNAs (siRNAs) to silence gene expression has proven to be invaluable for studying gene function in cultured mammalian cells. This chapter describes the use of siRNA to inhibit the expression of ERβ in renal cell carcinoma (RCC) and to further the understandi...
Source: Springer protocols feed by Biochemistry - October 12, 2015 Category: Biochemistry Source Type: news

Silencing Estrogen Receptor- & beta; with siRNA in Cultured Cells
Estrogen receptors & alpha; and & beta; (ER & alpha; and ER & beta;) are the two genomic estrogen receptors. ER & beta; was the second of these receptors to be discovered; its structure is similar to that of ER & alpha; but they are different in histological distribution. However, the functions of ER & alpha; versus ER & beta; are still unclear. The ability of small interfering RNAs (siRNAs) to silence gene expression has proven to be invaluable for studying gene function in cultured mammalian cells. This chapter describes the use of siRNA to inhibit the expression of ER & beta; in renal...
Source: Springer protocols feed by Biochemistry - October 11, 2015 Category: Biochemistry Source Type: news

RCC trials don’t mirror real-world experience
Researchers have found that real-world metastatic renal cell cancer patients being treated with tyrosine kinase inhibitors are often sicker than subjects in clinical trials for these drugs, leading to questions about safety for use in the very patients who need the drugs in clinical practice.10/06/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 6, 2015 Category: Cancer & Oncology Source Type: news

RCC trials don ’t mirror real-world experience
Researchers have found that real-world metastatic renal cell cancer patients being treated with tyrosine kinase inhibitors are often sicker than subjects in clinical trials for these drugs, leading to questions about safety for use in the very patients who need the drugs in clinical practice. 10/06/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 6, 2015 Category: Urology & Nephrology Source Type: news

Screening test predicts poor treatment response in mRCC
Expression levels of a key protein involved in tumor cell survival appear to predict response to standard first-line therapy in patients with metastatic clear cell renal cell carcinoma...10/01/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 1, 2015 Category: Cancer & Oncology Source Type: news

New drug improves outcome in treatment resistant kidney cancer
A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2015 Category: Science Source Type: news

New drug improves outcome in treatment resistant kidney cancer
(Dana-Farber Cancer Institute) A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 28, 2015 Category: Global & Universal Source Type: news

New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model has been validated for patients (pts) with mRCC in the second line TT setting. This model does not consider time from 1st to 2nd line therapy, tumor shrinkage during 1st line and tumor burden before 2nd line. We sought to investigate these factors in addition to IMDC ones.09/26/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2015 Category: Cancer & Oncology Source Type: news

Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial
We present efficacy and safety in a subset of pts who were treated with nivolumab beyond RECIST-defined progression to investigate the potential benefits of this treatment approach.09/26/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2015 Category: Cancer & Oncology Source Type: news

Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-ta
Lenvatinib (LEN) – n oral inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT – in combination with everolimus (EVE) improved median progression-free survival (PFS; 14.6 mo) vs EVE (5.5 mo; hazard ratio [HR] 0.40; 95% confidence interval [CI] 0.24–0.68; P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2015 Category: Cancer & Oncology Source Type: news

Bristol's Opdivo boosts kidney cancer survival
The successful outcome means Opdivo is the first so-called immune checkpoint inhibitor drug to show an improvement in overall survival in patients with renal cell carcinoma (RCC), a common type of kidney cancer.09/26/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 26, 2015 Category: Cancer & Oncology Source Type: news

First-Ever Survival Bump in Renal Cell Cancer (CME/CE)
(MedPage Today) -- Immune therapy may pave way to eventual cure (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 26, 2015 Category: Hematology Source Type: news

Cabozantinib in Kidney Cancer: Longest PFS YetCabozantinib in Kidney Cancer: Longest PFS Yet
Another presentation hailed as practice changing for renal cell carcinoma shows the longest progression-free survival yet in pretreated patients. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 25, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Finally, Drug Improves Survival in Pretreated Kidney CancerFinally, Drug Improves Survival in Pretreated Kidney Cancer
The first trial to show an improvement in survival in the second-line treatment of renal cell carcinoma has been hailed here as practice-changing. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 25, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
(University of Texas M. D. Anderson Cancer Center) For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma, a patient population for whom treatment options are currently limited. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2015 Category: Cancer & Oncology Source Type: news

Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited. Researchers at The University of Texas MD Anderson Cancer Center demonstrated a median overall survival benefit of 25 months with nivolumab, a Food and Drug Administration (FDA)-approved immunotherapy agent, compared with 19.6 months for everolimus, a current standard of care for patients with metastatic kidney cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 25, 2015 Category: Cancer & Oncology Source Type: news

Switching Therapies in Advanced Renal Cell Carcinoma
Following progression on first-line therapy, patients with renal cell carcinoma (RCC) often do not need to be hurried to second-line treatment, says David F. McDermott, MD. If there is existing disease that is not harming the patient, and the patient feels well, there is no reason to switch therapies, adds Eric Jonasch, MD.09/22/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 22, 2015 Category: Cancer & Oncology Source Type: news

What's Hot at ECC 2015? Immunotherapy and Rare CancersWhat's Hot at ECC 2015? Immunotherapy and Rare Cancers
New data showing long-term efficacy with immunotherapies and clinical benefit in renal cell carcinoma and neuroendocrine tumors will be presented. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

miR‐372 suppresses tumour proliferation
Up to now, the role of miR‐372 in renal cell carcinoma has remained unknown; in this study, we have aimed to reveal its functional importance in this tumour.09/08/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 8, 2015 Category: Cancer & Oncology Source Type: news

miR ‐372 suppresses tumour proliferation
Up to now, the role of miR ‐372 in renal cell carcinoma has remained unknown; in this study, we have aimed to reveal its functional importance in this tumour. 09/08/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 8, 2015 Category: Urology & Nephrology Source Type: news

Exelixis’ cabozantinib gets FDA breakthrough therapy status for renal cell carcinoma
Biopharmaceutical firm Exelixis has received breakthrough therapy designation from the US Food & Drug Administration (FDA) for its cabozantinib to treat patients with advanced renal cell carcinoma (RCC) who have received one prior therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 24, 2015 Category: Pharmaceuticals Source Type: news

Identifying Common Treatment Recommendations in Clear Cell Renal Cell Carcinoma
The authors of this study aimed to obtain treatment algorithms and develop decision trees through the analysis of treatment of mccRCC from experts at 11 institutions.08/06/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 6, 2015 Category: Cancer & Oncology Source Type: news

Eisai’s Lenvima gets FDA breakthrough therapy status for renal cell carcinoma
Japanese drugmaker Eisai's US subsidiary has obtained breakthrough therapy status from the US Food and Drug Administration (FDA) for its anticancer agent Lenvima (lenvatinib mesylate) to treat advanced or metastatic renal cell carcinoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 30, 2015 Category: Pharmaceuticals Source Type: news

FDA Grants Breakthrough Therapy Designation To Lenvatinib For The Potential Treatment Of Metastatic Renal Cell Carcinoma
Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the investigational use in patients with advanced or metastatic renal cell carcinoma (RCC) who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy.07/29/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 29, 2015 Category: Cancer & Oncology Source Type: news

Dalantercept plus axitinib versus placebo plus axitinib
Dr Martin Voss, (Memorial Sloan Kettering Cancer Centre, New York City, USA) talks to ecancertv at ASCO GU 2015 on part 1 of the DART study, a phase II randomised trial using dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma.07/22/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 22, 2015 Category: Cancer & Oncology Source Type: news

Potential therapeutic target in renal cell carcinoma
Axl plays multiple roles in tumourigenesis in several cancers. Here we evaluated the expression and biological function of Axl in renal cell carcinoma (RCC).07/17/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 17, 2015 Category: Cancer & Oncology Source Type: news

Argos fully enrolls its trial to test a cancer therapy
Argos is developing a therapy to treat metastatic renal cell carcinoma (mRCC) and hit the enrollment goal of 450 randomized patients. This is a Phase 3 trial, meaning it is one of the last major steps a drug developer takes before submitting an application with the U.S. Food and Drug Administration.07/16/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 16, 2015 Category: Cancer & Oncology Source Type: news

Kidney Cancer Association - Urology Care Foundation Research Scholar Award
Andrew C. Novick & P.H.M. de Mulder / AUA Urology Care Foundation Research Scholar Award Abraham Hakimi, MD Project Title: "Interrogation of the Sorbitol Pathway in VHL-Independent HIF driven Renal Cell Carcinomas" Institution: Memorial Sloan Kettering Cancer Center Mentor: James J. Hsieh, MD, PhD Sponsor: Kidney Cancer Association07/10/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2015 Category: Cancer & Oncology Source Type: news

Kidney Cancer Association - Urology Care Foundation Research Scholar Award
Andrew C. Novick& P.H.M. de Mulder / AUA Urology Care Foundation Research Scholar AwardAbraham Hakimi, MDProject Title: "Interrogation of the Sorbitol Pathway in VHL-Independent HIF driven Renal Cell Carcinomas"Institution: Memorial Sloan Kettering Cancer CenterMentor: James J. Hsieh, MD, PhDSponsor: Kidney Cancer Association07/10/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2015 Category: Urology & Nephrology Source Type: news

Xp11.2 translocation renal cell carcinomas in young adults
Little is known about the biological behavior of Xp11.2 translocation renal cell carcinomas (RCCs) as few clinical studies have been performed using a large sample size.07/01/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 1, 2015 Category: Cancer & Oncology Source Type: news

Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma
The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.06/28/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 28, 2015 Category: Cancer & Oncology Source Type: news

MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy
Gene modification of eukaryotic cells by electroporation is a widely used method to express selected genes in a defined cell population for various purposes, like gene correction or production of therapeutics. Here, we describe the generation of a cell-based tumor vaccine via fourfold transient gene modification of a human renal cell carcinoma (RCC) cell line for high expression of CD80, CD154, GM-CSF, and IL-7 by use of MIDGE® vectors. The two co-stimulatory molecules CD80 and CD154 are expressed at the cell surface, whereas the two cytokines GM-CSF and IL-7 are secreted yielding cells with enhanced immunological prop...
Source: Springer protocols feed by Cancer Research - June 26, 2015 Category: Cancer & Oncology Source Type: news

PRednisone Plus EVerolimus clinical trial
Title Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitor (PREV study).06/25/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 26, 2015 Category: Cancer & Oncology Source Type: news

Final results from the large sunitinib global expanded-access trial
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.06/19/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 19, 2015 Category: Cancer & Oncology Source Type: news

Pathways in Renal Cell Carcinoma: An Animated View
Learn more about a type of kidney cancer called advanced renal cell carcinoma (aRCC) and the pathways involved in the disease in this animated whiteboard...06/18/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 18, 2015 Category: Cancer & Oncology Source Type: news

Future perspectives for mTOR inhibitors in renal cell cancer
Everolimus is a mTOR inhibitor that demonstrates antitumor and antiangiogenic activities.06/16/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 16, 2015 Category: Cancer & Oncology Source Type: news

Argos Therapeutics: A Cure For Cancer?
AGS-003 for metastatic renal cell carcinoma ((mRCC)) in Phase III with the full patient enrollment expected in Q2-2014. The final results should come out in the second half of 2016. The primary endpoint of the study is the overall survival.05/23/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 23, 2015 Category: Cancer & Oncology Source Type: news

FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma
Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population.05/21/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 21, 2015 Category: Cancer & Oncology Source Type: news

2015 ASCO Annual Meeting
Abstracts in genitourinary cancers, including: Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US...05/14/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 14, 2015 Category: Cancer & Oncology Source Type: news

Revealing kidney cancer's secret
(University of California - Davis Health System) An international team of scientists, led by UC Davis nephrologist Robert Weiss, have used a sophisticated combination of proteomics and metabolomics to show how renal cell carcinoma reprograms its metabolism and evades the immune system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2015 Category: Cancer & Oncology Source Type: news

2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
Dateline City: KENILWORTH, N.J. New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), kno...
Source: Merck.com - Corporate News - May 13, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news

2015 Conquer Cancer Foundation of ASCO Young Investigator Award Funded by Kidney Cancer Association
Matthew Campbell, MD Chief Fellow, Hematology/Oncology Fellowship, UT MD Anderson Cancer Center New agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the ...
Source: Kidney Cancer Association - May 11, 2015 Category: Cancer & Oncology Source Type: news

2015 Conquer Cancer Foundation of ASCO Young Investigator Award Funded by Kidney Cancer Association
Matthew Campbell, MD Chief Fellow, Hematology/Oncology Fellowship, UT MD Anderson Cancer CenterNew agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the an...
Source: Kidney Cancer Association - May 11, 2015 Category: Urology & Nephrology Source Type: news

Analysis of Gene Expression of RCC by DNA Microaray in Patients treated with Sunitinib
Gene Evaluation of DNA expression from snap-frozen renal cell cancer tissue from 5 patients with locally advanced non-metastatic tumors, submitted to nephrectomy after being treated with 2 cycles of neoadjuvant Sunitinib...05/11/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 11, 2015 Category: Cancer & Oncology Source Type: news

2015 Conquer Cancer Foundation of ASCO Young Investigator Award
Layperson Summary  New agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the anti-body binds to CTLA-4, the immune system is able to stay activated an...
Source: Kidney Cancer Association - May 10, 2015 Category: Cancer & Oncology Source Type: news

Dr. Thomas Hutson on Drug Sequencing in Renal Cell Carcinoma
Seven new agents have been approved for renal cell over a relatively short period of time. That has made it difficult to determine which drugs should be used for first, says Hutson.04/28/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 28, 2015 Category: Cancer & Oncology Source Type: news

Metastatic renal cell carcinoma mimicking diverticulitis
We present an unusual case of metastatic renal cell carcinoma (RCC) mimicking diverticulitis in a 76-year-old man with a 16-year history of chronic lymphocytic leukaemia (CLL) and a 2 cm left renal mass.04/28/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 28, 2015 Category: Cancer & Oncology Source Type: news